Market anticipates Jiangxi Fushine Pharmaceutical's revenue to underperform industry figures, leading to a lower P/S. Investors foresee limited growth rates persisting, reducing their willingness to pay for the stock. If recent revenue trends persist, a share price reversal seems unlikely.

Investors in Jiangxi Fushine Pharmaceutical may hope for growth and profits as current stock performance disappoints. Long-term shareholders saw a 3% annual return over 5 years. The recent sell-off could signal an investment opportunity, if company fundamentals show long-term growth.